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 Introduction 
 Cutaneous lymphomas (CLs) are the second most 
common non-Hodgkin lymphomas with an estimated 
annual incidence of 1 new case per 100,000 inhabitants 
 [1] . Primary CLs by definition arise in the skin, while sec-
ondary CLs are manifestations of disseminated, primary 
nodal or extranodal lymphomas  [2] . Primary CLs include 
a broad spectrum of clinically and histologically hetero-
geneous lymphoproliferative diseases with diverse patho-
geneses and clinical manifestations. Around 80% of pri-
mary CLs are T-cell types (CTCL), 10–20% are B-cell 
types (CBCL), and the remaining number of CLs corre-
sponds to rare entities, such as CD4+/CD56+ haemato-
dermic lymphomas, deriving from type 2 dendritic cells. 
The diagnostic approach includes clinical, histological, 
immunohistochemical, imaging, haematological and 
molecular examinations  [3] .
 Classification 
 The latest classification system presented by the World 
Health Organization (WHO) and by the European Orga-
nization for Research and Treatment of Cancer is com-
patible with the WHO classification for haematopoietic 
and lymphoid neoplasias, includes additional entities and 
respects the organ-specific features of primary CLs  [4, 5] . 
This consensus classification system divides CLs into 3 
groups: CTCL and cutaneous natural killer cell lympho-
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mas, CBCL and precursor haematological neoplasms ( ta-
ble 1 ). Based on the different biological behaviour, CLs 
may be grouped into prognostic categories such as pre-
lymphomatous ‘abortive’ disorders, definite malignant 
lymphomas of low-grade malignancy and definite malig-
nant lymphomas of high-grade malignancy  [3] .
 Skin-Directed Therapies 
 It is recommended to identify the clinicopathological 
entity as given both in the classification system and the 
prognostic category to provide essential information on 
the behaviour of CLs and to allow the planning of the 
therapeutic strategy. The recommended approach for 
treatment is to aim for disease control, since definitive 
cure is usually not possible. Classical therapeutic modal-
ities can be divided into topical or systemic.  Table 2 shows 
a brief summary of the various standard topical treat-
ment options, which have been reviewed earlier elsewhere 
 [6] . In more advanced stages, various systemic treatment 
options such as glucocorticoids, extracorporeal photo-
pheresis, recombinant   -interferon (IFN-  ), retinoids, 
chemotherapeutic agents, bone marrow transplantation, 
fusion toxin denileukin difitox, histone deacetylase in-
hibitors, purin nucleoside analogue, monoclonal anti-
bodies, cytokines and vaccines are available. The goal of 
our present work is to highlight some of the promising 
new and experimental local therapies of CLs.
 Hexadecylphosphocholine 
 Hexadecylphosphocholine is an antineoplastic drug 
that inhibits tumour cell growth and might also exert im-
munoregulatory properties  [7, 8] .
 Dummer et al.  [9] treated 24 patients with 6% topical 
hexadecylphosphocholine (1 drop/10 cm 2 lesion) for 8 
weeks. Fifteen suffered from mycosis fungoides (MF), 7 
had CBCL and 2 had lymphomatoid papulosis. Of 15 
CTCL patients, 12 were evaluable. Two complete remis-
sions (CR), 4 partial remissions (PR) and 1 minor remis-
sion were observed. Of 7 CBCL patients, 6 were evaluable. 
One CR, 3 PR, 1 case of stable disease and 1 case of pro-
gressive disease were seen. Both patients with lympho-
matoid papulosis had a CR. Histological evaluation dem-
onstrated only a partial clearing of infiltrating lympho-
cytes in lesions that showed PR or CR clinically. Fifty-six 
percent of evaluable CL patients (10/18) achieved an ob-
jective response rate (PR and CR)  [9] .
Table 1. WHO-EORTC classification of CLs
CTCL and cutaneous NK cell lymphomas
MF
MF variants and subtypes
Folliculotropic MF
Pagetoid reticulosis
Granulomatous slack skin
Sézary syndrome
Adult T-cell leukaemia/lymphoma
Primary cutaneous CD30+ lymphoproliferative disorders
Primary cutaneous anaplastic large-cell lymphoma
Lymphomatoid papulosis
Subcutaneous panniculitis-like T-cell lymphoma
Extranodal NK/T-cell lymphoma, nasal type
Primary peripheral CTCL, unspecified
Primary aggressive epidermotropic CD8+ CTCL (provisional)
/ CTCL (provisional)
Primary CD4+ small/medium-sized pleomorphic CTCL
(provisional)
CBCL
Primary marginal zone CBCL
Primary cutaneous follicle centre lymphoma
Primary diffuse large CBCL, leg type
Primary diffuse large CBCL, other
Intravascular large B-cell lymphoma
Precursor haematological neoplasm
CD4+/CD56+ haematodermic neoplasm
(blastic NK cell lymphoma)
EORTC = European Organization for Research and Treat-
ment of Cancer; NK = natural killer.
Table 2. Classical topical treatment options in CL
Skin involvement Topical therapy
Limited/localized Corticosteroids
Nitrogen mustard
Carmustine
Local radiation
Topical retinoid (bexarotene)
Ultraviolet B
Psoralen + ultraviolet A
Generalized Corticosteroids
Mechlorethamine
Carmustine
Ultraviolet B 
Narrow-band ultraviolet B
Psoralen + ultraviolet A
Total skin electron beam therapy
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 Dumontet et al.  [10] performed a phase II trial to
evaluate 6% topical hexadecylphosphocholine solution
(2 drops/10 cm 2 lesion) for the treatment of 12 CTCL pa-
tients. All patients had received at least 1 prior systemic 
or topical treatment. The study drug was administered 
for 8 weeks, once per day during the first week, then twice 
every day for 7 weeks. Five patients were considered to be 
in CR, 2 patients had PR and 5 patients had stable disease. 
The overall response rate was 58% with a median dura-
tion of response of 12 months. The main side effects were 
moderate to mild pruritus or desquamation in 57% and 
50% of patients, respectively. No systemic or biological 
toxicity was observed  [10] . These studies have shown that 
hexadecylphosphocholine is a safe, simple and effective 
treatment in both untreated and previously treated pa-
tients in early patch form CL ( table 3 ).
 Methotrexate 
 Methotrexate (MTX) competitively inhibits dihydro-
folate reductase, therefore blocks DNA synthesis and pre-
vents mitosis  [11] . Oral or parenteral MTX is approved for 
the treatment of advanced MF; however, its systemic tox-
icity has precluded its use in patients with early-stage MF. 
Topical therapy of early-stage MF with the existing oral 
or parenteral MTX formulations is ineffective because of 
the inability of the drug to penetrate the stratum corne-
um from aqueous solutions  [12] . For this reason, MTX-
laurocapram was developed, which is a topical hydro-
philic gel formulation of MTX (1% wt/wt) with the pen-
etration enhancer laurocapram.
 Demierre et al.  [13] presented the results of a phase I/II 
study in 10 patients with early-stage MF who were treated 
topically with MTX-laurocapram. The gel formulation of 
the product was applied to the total body surface at daily 
doses of 12.5 or 25 g/m 2 , excluding the genital, perianal 
areas, nipples, face and skin under the breasts, on an ev-
ery-other-day basis for 24 consecutive weeks. Of 10 pa-
tients, 9 completed the study. At the end of the treatment 
phase (week 24), 3 patients (33%) had a moderate re-
sponse, 4 (44%) had a slight response and 2 (22%) had no 
response to treatment. In summary, a total of 7 (78%) pa-
tients demonstrated a slight to moderate response to 
treatment. Adverse events consisted of local skin reac-
tions of mild severity such as pruritus, rash, burning and 
dryness. No systemic reactions or clinically significant 
laboratory abnormalities were observed. Serum levels of 
MTX, as measured 24–48 h following the topical applica-
tion, were under the lowest limit of detection in all sam-
ples analysed  [13] .
 The results obtained in this study indicate that MTX-
laurocapram is safe and well tolerated, and it seems that 
systemic exposure to the drug is not significant. Despite 
the relatively low number of patients, efficacy outcomes 
were positive.
 Tazarotene 
 Retinoids, which are derivatives of vitamin A, modu-
late the differentiation and proliferation of keratinocytes 
and lymphocytes. Topical bexarotene in gel form is a syn-
thetic retinoid-X-receptor-selective retinoid, which has 
Table 3. Therapeutic approaches for the treatment of CTCL and CBCL with the antineoplastic drug hexadecylphosphocholine
Refer-
ences
Patients
enrolled
Patients
evaluated
Treatment
schedule
Clinical
response
Histological
clearance
Relapse
Dummer
et al. [9]
15 CTCL 12 1st week 1!/day, next 
7 weeks 2!/day, in PR 
or MR additional
4 weeks
2 CR, 4 PR,
1 MR
yes in 5 CR patients, 
but no decrease in 
lymphocyte numbers 
in the deeper dermis
n.a.
 7 CBCL 6 1 CR, 3 PR,
1 SD, 1 PD
Dumontet
et al. [10]
12 CTCL 12 1st week 1!/day,
next 7 weeks 2!/day
5 CR, 2 PR,
5 SD
n.a. none until a median follow-
up of 12 months in 2 CR +
1 PR patients;
in 3 patients, none between 
24 and 54 months
MR = Minor remission; SD = stable disease; PD = progressive disease; n.a. = not applicable.
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already been approved by the Food and Drug Adminis-
tration (FDA) for the treatment of refractory IA and IB 
MF lesions. Tazarotene is a synthetic retinoid in a gel or 
cream formula, which binds to the retinoic acid receptor 
  - and   -subtypes. As the latter is the dominant receptor 
in the skin, the selective binding capacity of tazarotene 
eliminates many side effects, which possibly occur when 
retinoic acid receptor subtypes are generally activated. 
The FDA has approved tazarotene for the treatment of 
psoriasis and acne vulgaris.
 Apisarnthanarax et al.  [14] conducted an open-label 
pilot study to assess the efficacy and tolerability of 0.1% 
tazarotene gel in the treatment of early patch or plaque 
MF lesions limited to less than 20% body surface area. 
Twenty patients were enrolled, 19 received treatment, and 
16 completed at least 4 weeks of topical therapy. Eleven of 
19 patients or 58% experienced at least moderate ( 1 50%) 
global improvement in all index lesions, and 35% of 99 
index lesions cleared completely. On the basis of grading 
of index lesions, mean significant differences were ob-
served after treatment in plaque elevation, scaling and 
erythema. Only pruritus did not change significantly and 
remained stable. Of 19 patients, 16 (84%) experienced 
mild or moderate local skin irritation manifested by peel-
ing, erythema, burning and tenderness that was man-
aged successfully with topical steroids or by reducing the 
frequency of treatment. Histological evaluations showed 
reductions in lymphocytic infiltrates and percentage of 
CD45RO+ lymphocytes, and increases in the percentage 
of CD8+ lymphocytes during the therapy course.
 The rate of irritation was similar or slightly higher 
than that reported with topical bexarotene gel for MF le-
sions, but the pilot study with tazarotene included few 
patients, was non-randomized, had no vehicle control 
and was susceptible to bias in lesion assessments  [14] . 
Nonetheless, these data suggest that tazarotene 0.1% gel 
combined with topical corticosteroids may be an effec-
tive adjuvant therapy for refractory MF lesions.
 Imiquimod 
 Imiquimod is a topical Toll-like receptor (TLR)-7 and 
TLR-8 agonist constitutively activating the transcription 
factor NF-  B, therefore inducing the production of pro-
inflammatory cytokines and chemokines including IFN-
  , IFN-  , interleukin-12 and tumour necrosis factor-  . 
This results in activation of antigen-presenting cells and 
the mounting of a profound T-helper 1 (Th1) antitu-
moural cellular immune response  [15] . The pro-inflam-
matory activity of imiquimod can also be correlated with 
adenosine receptor signalling pathways and receptor-in-
dependent reduction of adenylyl cyclase activity  [16] . At 
higher concentrations, imiquimod exerts a pro-apoptotic 
activity, which is dependent on bcl-2 proteins and in-
volves caspase activation  [16] . The cream formulation has 
been approved for the treatment of external genital and 
perianal warts, actinic keratoses and primary superficial 
basal cell carcinoma. As CTCL is dominated by T-helper 
2 cytokines, the enhancement of Th1 immune responses 
has a therapeutic role. So far several case reports and a 
few pilot studies exist, showing the efficacy of imiquimod 
in patients with different forms of CTCL such as MF  [17–
27] , CD30+ anaplastic large-cell lymphoma  [20, 23, 28] , 
primary cutaneous follicle centre lymphoma  [29] and 
primary CBCLs  [23, 25] .
 In a series of 6 CTCL patients, Deeths et al.  [21] ob-
served 50% clinical and histological clearing and a sig-
nificant improvement in clinical scores. Coors et al.  [23] 
observed CR in more than 50% of their CTCL patients, 
and additionally they observed a PR in 2 out of 3 CBCL 
patients; however, the effect of imiquimod seemed to be 
less potent in CBCL.
 Generally, treatment frequencies ranged from once 
daily to once weekly applications. Time to response was 
already reached after 2 weeks in some patients, and the 
duration of remission was between 5 and 45 months.
 Previous studies of Urosevic et al.  [30] showed that the 
clinical inflammatory reaction in response to imiquimod 
was correlated with the IFN-  gene signature and with 
the number of plasmacytoid dendritic cells in treated le-
sions, showing that these may have a role in the clinical 
response to imiquimod.
 Imiquimod treatment was generally well tolerated;
local irritation and erythema were common, but pruri-
tus, burning, pain, tenderness, infections, ulceration and 
postinflammatory discolouration occurred in some pa-
tients  [31] . Severe reactions usually developed in patients 
on an intensive regimen, which usually resolved within 
1–2 days after cessation and could be avoided by less fre-
quent applications  [17] . Although absorption into the cir-
culation is less than 1%, in rare cases systemic side effects 
were observed such as fatigue, fever, myalgia, nervous 
system impairment and gastro-intestinal symptoms 
 [32] .
 The case reports cited above and pilot studies demon-
strated that imiquimod might be effective in some cases 
with therapy-resistant lesions of CTCL as well as of CBCL 
with an acceptable safety profile ( table 4 ).
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 TG-1042 Adenovirus Vector 
 IFN-  is a cytokine with immunostimulatory, antitu-
mour, antiproliferative and anti-angiogenic properties 
 [33] .
 Intramuscular  [34] recombinant IFN-  has been in-
vestigated for the immunotherapy of CTCL with promis-
ing response rates, although severe toxicity was seen  [34] . 
Intratumoural delivery of recombinant IFN-  has been 
attempted to overcome systemic side effects  [35] ; how-
ever, the short half-life of the cytokine was a complicating 
factor.
 TG-1042 is a replication-deficient adenovirus vector 
expressing IFN-  to target CL lesions  [36] . Intralesional 
injection produces sustained local IFN-  protein levels 
while systemic IFN-  levels remain low.
 In a phase I/II study, all the 5 evaluable CBCL patients 
presented with a local response (3 CR and 2 PR), and 45% 
of the 29 evaluable CTCL patients responded to TG-1042 
treatment (7 CR and 6 PR). Out of the total 18 patients 
with objective local response, 15 showed systemic re-
sponse with the additional clearance of non-injected skin 
lesions (7 CR and 8 PR in non-treated tumours). CTCL 
subtypes, such as MF, Sézary syndrome and CD30+ ana-
plastic large-cell lymphoma, showed different response 
rates to TG-1042 injections. Clinical response was seen in 
8 out of 20 MF patients, but patients with Sézary syn-
drome did not benefit from treatment. All 3 evaluable 
patients with CD30+ anaplastic large-cell lymphoma re-
sponded with a CR in the treated lesions. It seems that 
more localized lesions in earlier stages of the disease in 
conjunction with CD30 expression respond better to 
treatment. In general, CBCL lesions are easily accessible 
Table 4. Therapeutic approaches for the treatment of CTCL and CBCL with the immune response modifier imiquimod
References Patients
enrolled
Number
of lesions
Fluences Time to
response
Clinical
response
Histological response Relapse 
Suchin et al. [17] 1 2 CTCL 1!/day 4 months 2 CR yes, 1 lesion partly none in 10 months
Dummer et al. [18] 1 multiple CTCL 1!/day 8 weeks 1 CR n.a. none in 12 months 
Chong et al. [19] 3 3 CTCL 1!/day 32 weeks 3 PR1 n.a. n.s.
Didona et al. [20] 2 2 CTCL 3!/week 8 months 2 CR yes, 1 lesion was evaluated none in 8 months
Deeths et al. [21] 6 23 CTCL 1–3!/week 4 weeks 50%2 yes, 3 lesions out of 63 none in 24 months
Ardigo et al. [22] 1 1 CTCL 5!/week 24 weeks 1 CR yes none in 6 months
Coors et al. [23] 5 9 CTCL 3–5!/week 8–16 weeks 5 CR, 2 PD, 2 NR n.a. none in 5–45 months3 11 CBCL 12–52 weeks 8 PR, 3 NR none in 19–42 months
Chiam and Chan [24] 1 1 CTCL 3–4!/week 5 months 1 CR n.a. none in 6 months
Stravrakoglou
et al. [25]
1 multiple FCL 1!/day, then
2–4!/week
2–12 weeks multiple CR yes none in 24 months
Martínez-González
et al. [26]
4 11 CTCL 3!/week 3–14 months 11 CR yes, 3 lesions out of 43 follow-up ongoing
Ariffin and
Khorshid [27]
2 1 CTCL 2!/week,
then 1!/day
12 weeks 1 CR n.a. none in 6 months
Ehst et al. [28] 2 3 CTCL 2–7!/week4 6–16 weeks 2 CR n.a. patient 1: follow-up 
ongoing5
patient 2: none in 4 
months
FCL = Follicle centre lymphoma; PD = progressive disease; NR = no response; n.a. = not applicable; n.s. = not stated.
1 Treated lesions demonstrated a mean decrease in surface area of 8.9%.
2 The physician’s global assessment scale was used to judge overall patient response. No change in 1 patient, slight improvement in 2 patients, moder-
ate improvement in 1 patient, marked improvement in 1 patient and almost clear in 1 patient.
3 One lesion per patient (index) was chosen for histological evaluation.
4 Concurrent administration of MTX and imiquimod.
5 Two lesions were treated in patient 1, one of the lesions healed and never recurred.
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for treatment and responded very well to TG-1042; there-
fore, a larger multicentre phase II study currently evalu-
ates the response rates in different CBCL subtypes  [37] .
 Based on a recent work of Urosevic et al.  [38] , it ap-
pears that both the expression of the transgene and the 
adenoviral vector itself contribute to the regression of 
skin lesions. Gene expression profiles of skin lesions ob-
tained from CL patients before and after treatment with 
TG-1042 revealed a distinct gene signature consisting
of IFN-  - and numerous IFN-  -inducible genes. IFN-  
very likely promotes the immunogenicity of the tumour, 
while type I IFNs, on the other hand, exhibit profound 
antitumoural effects by acting on host immune cells 
 [38] .
 Treatment with TG-1042 was well tolerated, usually 
with grade 1 or 2 adverse events such as injection site re-
actions, flu-like syndrome, fatigue and possibly dose-de-
pendent headache. Unspecified colitis, vomiting follow-
ing vasovagal syncope and transient fever were reported 
as possibly related side effects.
 This therapy induced regression in CTCL and CBCL 
patients both at the injection site and systemically with 
tolerable side effects ( table 5 ).
 Rituximab 
 Tumoural pre-B and mature B cells express the CD20 
antigen, which can be targeted by rituximab, a human-
mouse chimeric monoclonal antibody. Rituximab kills 
CD20+ tumour cells by directly inducing apoptosis, by 
triggering complement-mediated lysis and by antibody-
dependent cell-mediated cytotoxicity  [39, 40] .
 Nodal B-cell lymphoma can be successfully treated 
with intravenous rituximab infusion as monotherapy or 
in combination with other agents  [41–43] .
 Heinzerling et al.  [44] reported for the first time the 
use of intralesional rituximab in 2 patients with primary 
CBCL. One patient had progressive nodular lesions on 
the scalp and on the face. The other patient presented 
with recurrence of tumour nodules in different body 
parts. Rituximab was injected 3 times a week, each time 
30 mg, followed by a 3-week treatment-free period. An 
inflammatory response in the injected lesions was ob-
served approximately 2–3 h after each injection and last-
ed for a few hours. After 6–9 injections, some of the nod-
ules flattened and diminished in size, and others, includ-
ing some that were not treated, had completely resolved. 
No adverse effects occurred except pain during or short-
ly after injection and, in 1 patient, a slight rise in body 
temperature. Due to the treatment, a prolonged complete 
disappearance of B cells from peripheral blood samples 
was observed  [44] .
 Later on Kerl et al.  [45] treated 8 primary CBCL pa-
tients with rituximab. Patients selected for treatment had 
follicle centre (4 patients) and marginal zone (4 patients) 
lymphoma. These are the most frequent CBCL entities, 
which have an indolent course and rarely disseminate to 
internal organs, but their incidence of recurrence is high 
 [5, 46] . Six patients received intralesionally 10–30 mg 
rituximab, 3 times weekly for 1 or 2 cycles with a 4-week 
interval. Two patients were treated with intravenous 
rituximab and received 375 mg/m 2 , once weekly for 4 
consecutive weeks. All patients reached CR, and the 2 pa-
tients treated intravenously did not relapse during a fol-
low-up period of 18–24 months. Four of 6 patients treated 
intralesionally presented a relapse of new lesions at an-
other site within a mean of 6 months after treatment. 
However, the injected lesions did not recur. New lesions 
also responded to another cycle of intralesional ritux-
imab  [45] .
 Intralesional rituximab therapy was well tolerated 
without severe side effects. All patients reported moder-
ate pain during the injection procedure. On the other 
hand, no burning or erythema was reported.
Table 5. Therapeutic approaches for the treatment of CTCL and CBCL with a replication-deficient adenovirus vector expressing
IFN- (TG-1042)
Reference Patients
enrolled
Patients
evaluated
Treatment
schedule
Local
response
Global
response
Histological
clearance
Relapse
Urosevic [37] 32 CTCL 29 3!1011 TVP TG-1042 i.t. 7 CR, 6 PR 15 n.s. n.s.
6 CBCL 5 for up to 4 cycles 3 CR, 2 PR
TVP = Total viral particles; i.t. = intratumourally; n.s. = not stated.
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 It seems that this treatment has a potential advantage 
when lesions are localized at sites that are difficult to treat 
with radiotherapy or surgery and when secondary scar-
ring or alopecia is expected to occur. In summary intra-
lesional rituximab is a valuable alternative option for the 
treatment of CBCL, but the risk of relapse was relatively 
high ( table 6 ).
 Photodynamic Therapy 
 Photodynamic therapy (PDT) requires the presence of 
a photosensitizer, light and oxygen. In dermatology, 5-
aminolevulinic acid (5-ALA) and the methyl ester of 5-
ALA are the most commonly used photosensitizers, 
which may semiselectively accumulate in abnormal skin 
tissue and are converted to protoporphyrin IX, inducing 
a photochemical and phototoxic skin reaction through 
reactive oxygen radicals in the presence of visible light 
 [47, 48] . Following serial evaluations immunological ef-
fects have been additionally described.
 Boehncke et al. showed that the photosensitizer is 
mainly taken up by the lymphocytes in CL plaques  [49] 
and that PDT has the capability to inhibit proliferation of 
transformed T cells  [50] .
 Orenstein et al.  [51] observed that malignant cells in 
CTCL plaques have a greater ability to convert ALA into 
protoporphyrin IX than peripheral blood lymphocytes.
 The observations of Rittenhouse-Diakun et al.  [52] 
might explain the greater susceptibility of malignant 
lymphocytes to photosensitizers. They found that acti-
vated lymphocytes express higher levels of CD71 (trans-
ferrin receptor), making them able to take up more iron 
and, therefore, produce more protoporphyrin IX.
 Based on several existing reports  [51, 53–68] , it can be 
concluded that PDT treatment of CTCL lesions is of ben-
efit in most (CR in more than 86% of cases presented in 
 table 7 ) but not all patients. The numbers of treatments 
to reach CR were usually between 1 and 12, and remission 
periods were between 3 and 106 months ( table 7 ). Lesions 
in remission had a peculiar histological appearance, since 
atypical lymphocytes continued to be present in the der-
mis.
 A recent study performed by Mori et al.  [69] used 
ALA-PDT and red light at the standard dose used for bas-
al cell carcinoma to treat 3 patients with single early 
CBCL lesions. They reported CR following a single ses-
sion in all of the patients, with a follow-up of between 8 
and 17 months.
 PDT therapy was tolerated well; in most cases erythe-
ma, oedema, postinflammatory hyperpigmentation, local 
discomfort, burning and pain were reported. In rare cas-
es, superficial blisters, erosion and ulceration occurred.
 Based on small studies with few patients and numer-
ous case reports, it seems that CL patients with localized 
lesions can benefit most from PDT. It is very likely that 
lymphocytes in the plaque are only inactivated but not 
eliminated and remission periods are highly variable, 
therefore a regular follow-up is necessary.
 Further studies will be necessary to evaluate whether 
the combination with other therapeutic modalities en-
hances efficacy. Umegaki et al.  [64] have already report-
ed a case of cutaneous anaplastic large-cell lymphoma, 
which was effectively treated by PDT prior to radiother-
apy.
 308-nm Excimer Laser 
 UVB phototherapy has been used for treating various 
skin diseases including CL. Different CL forms respond 
well to either broad-band or narrow-band UVB photo-
Table 6. Therapeutic approaches for the treatment of CBCL with the human-mouse chimeric monoclonal antibody rituximab
References Patients
enrolled
Treatment schedule Time to
response
Clinical
response
Histological
response
Relapse
Heinzerling
et al. [44]
2 30 mg i.l. 3!/week,
1 week treatment, 3-week
treatment-free period
6–9 injections CR, PR
(numbers n.s.)
no (only 2
lesions assessed)
in 12 months 1 new 
lesion, otherwise n.s.
Kerl
et al. [45]
6 10–30 mg i.l. 3!/week for 1 or
2 cycles with a 4-week interval
CR after 1 or
2 cycles
6 CR n.s. 4 patients in
4–8 months
i.l. = Intralesionally; n.s. = not stated.
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therapy. Recently, it has been reported that a 308-nm xe-
non chloride (XeCl) UVB laser is highly effective for 
treating psoriasis  [70] , and, over the past few years, sev-
eral excimer laser studies have been published for the 
treatment of early-stage MF.
 It seems that effective induction of T-cell apoptosis is 
responsible for the greater clinical efficacy of XeCl laser 
compared to other UVB sources  [71, 72] .
 Nistico et al.  [73] treated 5 patients with a total of 10 le-
sions with a clinical and histological diagnosis of primary 
CL with repeated applications of the XeCl laser, until CR 
was achieved or up to a maximum of 10 applications. The 
cumulative UVB dose was between 6 and 12 J/cm 2 . After 
a 1-year follow-up, all patients were in CR  [73] .
 Passeron et al.  [74] treated 5 patients with patch-stage 
or plaque-stage primary CL in a XeCl laser study. The 50 
mJ/cm 2 initial fluences were increased by 100 mJ/cm 2 ev-
ery 2 sessions. Treatment was administered twice weekly 
until clinical clearance or minimal residual activity was 
achieved. A CR was obtained for 4 of the 5 patients, and 
minimal residual activity (PR) was observed in the fifth. 
Clinical healing was obtained in 11–21 sessions, with a 
cumulative dose ranging from 2.4 to 16.1 J/cm 2 . No clin-
ical recurrence was noted 3 months after the end of the 
sessions.
 Later the same group conducted a XeCl laser trial with 
10 MF patients. A total of 29 lesions were treated as de-
scribed in their previous study. The mean cumulative 
dose ranged from 1.3 to 16.1 J/cm 2 . After treatment ses-
sions, 25 CR and 3 PR were observed, and 1 lesion did not 
respond. Follow-up was performed in 19 lesions for a me-
dian period of 8–26 months; 13 persistent CR, 3 contin-
ued PR and in 2 cases relapses were observed, and 1 lesion 
remained non-responsive. Histology was consistent with 
clinical results, except for 1 case with persistence of a few 
mycosis cells in the epidermis despite a clinical appear-
ance of healing  [75] .
 Afterwards this treatment option was studied in lym-
phomatoid papulosis  [76] and CD30+ cutaneous lympho-
proliferative disorders  [77] .
 Side effects were manageable; usually slight erythema, 
pruritic sensation and transient hyperpigmentation were 
noticed in all patients, with spontaneous resolution. In 
the case of intense erythema, the sessions were cancelled 
and the fluence at the next treatment corresponded to the 
highest dose that did not induce adverse effects.
 Table 8 briefly summarizes the results obtained with 
the 308-nm excimer laser for various CL forms and lym-
phomatoid papulosis.
Table 7. Therapeutic approaches for the treatment of CTCL with PDT
References Patients
enrolled
Number
of lesions
Number of
treatments
Clinical
response
Histological
clearance
Relapse 
Svanberg et al. [53] 2 4 1–2 2 CR n.a. none in 14 months
Wolf et al. [54] 2 3 4–5 3 CR yes none in 3–6 months
Ammann and Hunziker [55] 1 1 1 1 CR no n.a.
Stables et al. [56] 1 1 2 1 CR 2/3 of the lesion1 none in 12 months
Eich et al. [57] 2 2 8–12 1 CR, 1 PR yes in CR and PR in PR after 4 weeks, in CR none in 24 months
Wang et al. [58] 1 3 3 3 CR n.a. none in 33 months
Orenstein et al. [51] 2 6 1–2 6 CR yes none in 24–27 months
Edstrom et al. [59],
Edstrom and Hedblad [60]2
10 12 2–11 7 CR, 2 PR, 3 NR yes in CR and PR in CR, none in 4–21 months (1st follow-up),
71–106 months (2nd follow-up only 4 patients)3
Markham et al. [61] 1 1 5 1 CR yes none in 12 months
Leman et al. [62] 1 2 2 2 CR yes none in 12 months
Paech et al. [63] 1 2 2 2 CR yes none in 12 months
Umegaki et al. [64] 1 1 9 1 CR yes none in 24 months4
Coors and von den Driesch [65] 4 7 1–7 7 CR n.a. none in 14–18 months
Zane et al. [66] 5 5 1–9 4 CR, 1 PR n.a. none in 12–34 months
Hegyi et al. [67] 1 1 3 1 CR yes none in 16 months
Recio et al. [68] 2 2 3 2 CR yes none in 24 months
NR = No response; n.a. = not applicable.
1 Three areas within the lesion were irradiated with 5, 10 and 20 J/cm2 of white light after 20% topical 5-ALA pretreatment. After 3 months no lym-
phocytic infiltration was seen in the 2 areas irradiated with 10 and 20 J/cm2 (2/3 of the lesion).
2 The original study was published in 2001 [59], and the long-term follow-up was published in 2008 [60].
3 PDT with topical 5-ALA was combined with radiotherapy for the treatment of cutaneous CD30+ anaplastic large-cell lymphoma.
4 Following PDT the remaining lesion underwent radiation therapy and a clinically disease-free condition resulted.
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 Conclusions and Future Perspectives 
 Skin-directed therapies using topical formulations are 
preferred for the majority of patients with early-stage CL, 
which usually include topical corticosteroids, topical 
chemotherapeutic agents, the topical retinoid bexaro-
tene, electron beam therapy and phototherapy. Not all 
patients respond to these therapies, and some of them be-
come refractory to treatment  [78] . In this field there are 
interesting developments, but there are often insufficient 
data to compare the efficacy and side effects of available 
and possible future therapies.
 The topical administration of antineoplastic agents 
such as MTX is very likely restricted by the poor diffusion 
of the drug across the stratum corneum. Therefore at-
tempts have been made to increase transdermal trans-
port through electroporation  [79, 80] and using an erbi-
um:YAG laser in animal models. Both techniques signif-
icantly enhanced the permeation of MTX. The enhancing 
effect was more pronounced after applying the laser. 
Electroporation treatment resulted in a twofold increase 
in MTX flux, laser pretreatment produced a 3- to 80-fold 
enhancement and combination of laser and electropora-
tion pretreatment resulted in a higher drug permeation 
than either technique alone  [80] .
 Retinoids have been used for years as monotherapy 
and in combination for CTCL treatment. Rexinoids have 
been available since the approval of oral bexarotene for 
CTCL. Topical retinoids and rexinoids, especially the se-
lective ones, have fewer side effects than the oral ones; 
therefore, the use of retinoids and rexinoids will require 
strategies to identify novel receptor-selective subtypes 
with a better therapeutic index to decrease the possible 
side effects.
 Restoring Th1 immunity in CL is an important thera-
peutic approach, therefore the role of IFNs (IFN-  and in 
recent years IFN-  ) and immunomodulators, which are 
potent IFN inducers, is becoming more important. Im-
iquimod (TLR-7 and TLR-8 agonist), a potent IFN-  in-
ducer, has been reported to be beneficial for some pa-
tients with localized stage IA MF, and agents other than 
imiquimod are also under investigation. Recent data 
showed that EAPB0203, a member of the imidazoqui-
noxaline family, may have a future therapeutic role in the 
treatment of HTLV-I-negative peripheral T-cell lympho-
ma  [81] , and it has also been shown that the novel tellu-
rium immunomodulator AS101 induces a dose-depen-
dent G 2 /M arrest in CTCL cell lines and delays tumour 
growth in mice, when injected intratumourally  [82, 83] . 
Formerly it was shown that a replication-deficient adeno-
virus, which carries the IFN-  gene, has a therapeutic ef-
fect for the treatment of CL. A phase I/II clinical trial in 
CTCL and CBCL patients was recently completed, and 
clinical studies are still ongoing in CBCL patients  [36, 
37] .
 The oligonucleotide CpG-7909, which is a TLR-9 ago-
nist, has shown promising results in CTCL patients  [84] , 
and a phase I/II study has been initiated to investigate 
CpG-7909 together with radiation therapy in low-grade 
B-cell lymphoma or MF patients.
 Antibodies against antigens on the surface of lympho-
ma cells have an emerging therapeutic role. CD20 is 
Table 8. Therapeutic approaches for the treatment of CTCL and lymphomatoid papulosis with 308-nm excimer laser
References Patients
enrolled
Number
of lesions
Sessions Cumulative
UVB dose, J/cm2
Clinical response Histological clearance Relapse
Nistico
et al. [73]
5 10 4–10 6–12 10 CR yes none in 12 months
Passeron
et al. [74]
5 5 11–21 2.4–16.1 4 CR, 1 MR yes in 3 patients
without atypical cells
none in 3 months
Passeron
et al. [75]
10 29 6–46 1.3–16.1 25 CR, 3 PR, 1 NR yes, consistent with
clinical response
none in 8–26 
months, 19 lesions
Kontos
et al. [76]
3 multiple 13–22 0.4–0.5 patient 1: 75% CR1;
patient 2: 100% CR;
patient 3: NR
patient 1: n.a.;
patient 2: yes;
patient 3: n.a.
in patient 2,
none in 13 months
MR = Minor remission; NR = no response; n.a. = not applicable.
1 Patient 1 had lymphomatoid papulosis, patient 2 and 3 had MF.
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strongly expressed on the surface of malignant B cells 
and can be targeted by rituximab  [39, 40] . In the case of 
primary CBCLs, intralesional therapy with rituximab 
has already been found to be effective  [44, 45] . In com-
parison with intravenous administration, intralesional 
application of the drug allows the use of lower doses and 
fewer side effects. Recently a clinical study has been de-
signed to investigate the antitumour activity of rituximab 
combined with CpG-7909 in patients with relapsed/re-
fractory CD20+ B-cell non-Hodgkin’s lymphoma  [85] . 
Objective responses occurred in 24% of patients overall 
and in 50% of patients who after combination therapy 
received CpG-7909 alone for an additional 20 weeks; this 
cohort included 2 patients with rituximab-refractory dis-
ease. Most common adverse events were mild to moder-
ate systemic flu-like symptoms, injection site reactions 
and neutropenia  [85] . Based on these results, it would be 
reasonable to check this combination therapy in primary 
CBCL patients.
 Phototherapy has been utilized for decades in the 
treatment of CL and recently it has been shown that PDT 
is also an effective, non-invasive and safe therapeutic ap-
proach  [86] . Reports already exist, which suggest that this 
therapeutic modality can be effectively used prior to ra-
diotherapy  [64] . Treatment of ALA-PDT with PUVA rep-
resents a promising option as it was shown that this com-
bination inhibits the proliferation of a lymphoma cell line 
in vitro  [87] .
 The XeCl laser is a new and very useful form of UVB 
phototherapy. During XeCl laser therapy, the overall 
treatment time is shorter, the treatments are less frequent 
and the cumulative UV dose is significantly lower than 
those used in standard UV phototherapies; therefore, it is 
presumed that the lower therapeutic cumulative dose of 
the XeCl laser involves a lower risk of carcinogenesis. It 
is considered that longer-wavelength UVB phototherapy 
would be ideal for the treatment of thick skin lesions, 
while short-wavelength UVB radiation would be optimal 
for the treatment of thin ones. To further optimize treat-
ment results, the surface of skin lesions can be moistened 
to enhance the penetration of radiation. As with other 
UV therapies, combination therapy seems to be the next 
step to improve efficacy  [88] .
 Arsenic compounds such as As 2 O 3 have been shown 
to induce cell death by the inhibition of bcl-2. In acute 
promyelocytic leukaemia, this treatment modality led to 
CR in 90% of the patients  [89–91] . In patients with Sézary 
syndrome, this kind of therapy has not been successful as 
As 2 O 3 levels were low in the skin  [92] . Tun-Kyi et al.  [93] 
have shown that As 2 O 3 induced apoptosis of CTCL cells 
by down-regulating transcription factors that stimulate 
the expression of anti-apoptotic genes. Local injection of 
As 2 O 3 induced tumour regression in MF tumour-bear-
ing mice  [93] . These results demonstrate that As 2 O 3 could 
be a novel local treatment option for CTCL.
 In summary, ongoing and future standardized clinical 
trials will hopefully provide new data regarding experi-
mental skin-directed treatment options for CL patients. 
As with other already well-established treatment options, 
combination therapy seems to be a logical future step to 
improve efficacy.
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